Nikhil Prasad Fact checked by:Thailand Medical News Team Oct 24, 2024 1 month, 2 weeks, 4 days, 22 hours, 24 minutes ago
Medical News: A new SARS-CoV-2 variant, XEC, is making headlines as researchers uncover its heightened ability to evade immune defenses. Through extensive studies, scientists have determined that the XEC variant achieves this by adding new glycosylation sites on the Spike protein’s N-terminal domain (NTD). This breakthrough finding highlights the ongoing evolution of SARS-CoV-2 and raises concerns about the potential challenges it poses to global public health.
SARS-CoV-2 XEC Variant Shows Enhanced Immune Evasion through NTD Glycosylation
Understanding the New Variants: KP.3.1.1 and XEC
The research, conducted by scientists from multiple prestigious institutions, including the Biomedical Pioneering Innovation Center (BIOPIC) and the College of Future Technology at Peking University, delved into the characteristics of two specific SARS-CoV-2 variants, KP.3.1.1 and XEC. These variants are currently gaining prevalence in Europe and North America, with XEC standing out due to its rapid expansion and novel mutations.
KP.3.1.1, which evolved from the KP.3 strain, has already surpassed its predecessor to become the dominant strain worldwide. The XEC variant, a recombinant variant of KS.1.1 and KP.3.3, carries two significant mutations - S31del and T22N - on its NTD, which are suspected of introducing new glycosylation sites. According to the researchers, these mutations may contribute to an enhanced ability of the virus to evade neutralizing antibodies, a phenomenon they thoroughly investigated in this
Medical News report.
The Study’s Methodology and Key Findings
The study employed cutting-edge techniques such as surface plasmon resonance (SPR) to evaluate the binding affinity between the Spike protein and the human ACE2 receptor. Using pseudovirus assays in Vero cells, the researchers further explored the infectivity and immune evasion capabilities of these variants. KP.3, KP.3.1.1, and XEC all showed a high affinity for binding to the ACE2 receptor, which is critical for the virus to enter human cells. However, despite the NTD glycosylation mutations, the overall receptor-binding capability remained comparable to that of KP.3.
One of the most notable findings was the enhanced immune evasion observed in the XEC variant. Compared to KP.3 and even the newly dominant KP.3.1.1, XEC demonstrated increased resistance to neutralizing antibodies found in the plasma of individuals previously infected with other variants. Specifically, XEC was able to evade antibodies from individuals who had been reinfected after prior exposure to the BA.5/BF.7 and JN.1 strains. The researchers noted a significant decrease in neutralizing activity against XEC, which raises concerns about the effectiveness of existing vaccines and treatments in combating this variant.
The Role of NTD Glycosylation in Immune Evasion
The introduction of new glycosylation sites through mutations in the NTD plays a pivotal role in the immune evasion abilities of KP.3.1.1 and XEC. Glycosylation refers to the attachment of sugar molecules
to proteins, which can alter the way these proteins are recognized by the immune system. The research team hypothesized that the new glycosylation patterns in the NTD could affect how neutralizing antibodies bind to the virus, thereby making it more difficult for the immune system to neutralize the variant.
Further investigation revealed that the mutations in XEC also enhance the virus's ability to evade monoclonal antibodies, which are crucial in treatments for COVID-19. These antibodies typically target specific epitopes on the receptor-binding domain (RBD) of the Spike protein, but the glycosylation mutations in XEC appear to have an allosteric effect, meaning they can influence antibody binding even at distant sites on the protein. This discovery emphasizes the growing complexity of SARS-CoV-2 mutations and the challenges they pose in developing effective therapies.
Implications for Public Health and Vaccination
The enhanced immune evasion capabilities of the XEC variant suggest that current vaccines, which primarily target the Spike protein’s RBD, may be less effective against emerging variants like XEC. This potential reduction in vaccine efficacy is concerning, especially given the variant’s rapid spread across multiple regions. The findings underscore the need for continuous monitoring of SARS-CoV-2 variants and the development of updated vaccines and therapies that can address these new mutations.
Additionally, the study’s results highlight the importance of global surveillance efforts in tracking the emergence and spread of new variants. Researchers involved in the study, including Yuanling Yu and Fei Shao from Changping Laboratory in Beijing, emphasized that the rapid global spread of variants like XEC requires coordinated international efforts to mitigate their impact on public health.
Conclusion: XEC’s Growing Threat
In conclusion, the study on KP.3.1.1 and XEC reveals crucial insights into the evolving immune evasion strategies of SARS-CoV-2. Both variants, particularly XEC, demonstrate enhanced resistance to neutralizing antibodies, posing a significant threat to global health efforts in controlling the virus. The introduction of new glycosylation sites on the NTD appears to be a key factor in this immune evasion, affecting the virus's interaction with both convalescent plasma and monoclonal antibodies.
These findings raise important questions about the future trajectory of the pandemic, as new variants like XEC continue to evolve and spread. Scientists are now calling for further structural studies to explore the exact mechanisms behind these glycosylation-induced changes and how they influence the virus’s infectivity and immune evasion.
The study findings were published on a preprint server and are currently being peer reviewed.
https://www.biorxiv.org/content/10.1101/2024.10.23.619754v1
For the latest COVID-19 News, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/news/new-sars-cov-2-xec-2-strain-with-nsp5-mutation-v73f-detected-in-17-countries-could-be-a-potential-winter-threat
https://www.thailandmedical.news/news/the-sars-cov-2-variants-that-could-drive-the-fall-winter-wave-xec-xed-mb-1-1-mw-1-and-xdv-1-1
Share
Tweet
Share
